Detailed Medication Guide and Dosage Analysis of Ixazomib/Enleri

Ixazomib, also known as Ixazomib, is a new generation of proteasome inhibitor. It effectively interferes with the protein balance in malignant plasma cells by accurately inhibiting the chymotrypsin-like activity of the 20S proteasome, thereby achieving therapeutic purposes. Compared with the first-generation proteasome inhibitor bortezomib, the oral form of ixazomib significantly improves bioavailability, brings a more convenient treatment experience to patients, and is expected to improve patients' medication compliance and overall quality of life. Verified by a series of clinical trials, ixazomib has demonstrated excellent therapeutic efficacy and safety whether used as a monotherapy or in combination with standard treatment drugs for multiple myeloma (MM) such as lenalidomide and dexamethasone.

As for the dosing guidance of ixazomib, the recommended starting dose is4 mg. Patients should choose oral administration on days 1, 8, and 15 of each 28-day treatment cycle. At the same time, lenalidomide is recommended to start at 25 mg and be taken continuously from day 1 to day 21 of the treatment cycle; the recommended starting dose of dexamethasone is 40 mg, which should be taken on days 1, 8, 15 and 22 of each cycle. The entire treatment regimen should be continued until the disease progresses or the patient becomes unable to tolerate the side effects of the medication.

When taking ixazomib, patients should ensure it is taken on the same day and at approximately the same time point during the first three weeks of each four-week cycle to ensure stable blood concentrations. In addition, to avoid the impact of food on drug absorption, it is recommended to take it at least one hour before or two hours after a meal. Before starting treatment, medical staff should fully communicate with patients, emphasize the importance of following dosing instructions, and instruct patients to take recommended doses strictly as directed, as overdose may pose a fatal risk.

Ixazomib is available in capsule form. If the patient delays or misses a dose for any reason, the dose should be taken only after at least 72 hours have passed since the next scheduled dose. If the next scheduled dose is less than 72 hours away, you should not take the missed dose, let alone double the dose to make up for the missed dose. If vomiting occurs after taking the medicine, the patient does not need to take the medicine again and only needs to continue taking the medicine according to the original plan at the next scheduled time.